Randomized Trialhigh evidence
Propionic acid in multiple sclerosis: a phase 2b, double-blind, randomized placebo-controlled trial.
Brain : a journal of neurology·July 6, 2026·PMID 42402345
Why it matterssNfL is a validated biomarker of neuroaxonal injury in MS, and its reduction suggests a potential neuroprotective effect. This trial provides the first randomized evidence that a gut-derived metabolite supplement may attenuate ongoing damage even in patients on effective disease-modifying therapies.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled